Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CCND3 | P30281 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062564 | 0.81 | IGF1R (0.54) | ALKIGF1RAURKACCNA2CDK2 | |
| SCHEMBL29558030 | 0.78 | AURKA (0.41) | JAK3FLT1FLT4KDRAURKA | |
| SCHEMBL28717548 | 0.78 | AURKA (0.41) | JAK3FLT1FLT4KDRAURKA | |
| SCHEMBL28969585 | 0.77 | CDK2 (0.43) | MAPK9MAPK10PIN1ALKIGF1R | |
| SCHEMBL30394905 | 0.77 | AURKA (0.46) | MAPK9MAPK10ALKAURKACCNA2 | |
| SCHEMBL24752703 | 0.77 | ALK (0.44) | MAPK9MAPK10PIN1ALKINSR | |
| SCHEMBL30833698 | 0.77 | ULK1 (0.43) | MAPK9MAPK10PIN1ALKIGF1R | |
| SCHEMBL29019902 | 0.77 | AURKA (0.46) | MAPK9MAPK10ALKAURKACCNA2 | |
| SCHEMBL30184233 | 0.77 | ALK (0.44) | MAPK9MAPK10PIN1ALKINSR | |
| SCHEMBL30833632 | 0.77 | BCL6 (0.50) | MAPK9MAPK10ALKCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| EP-1272477-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-7153964-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20030149064-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-1272477-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064654-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149064-A1 | Pyrimidine compounds | CDK2, CCNI, CCNY | JAK3 214/4885MAPK9 476/4885MAPK10 1424/4885 |
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | JAK3 1059/4885MAPK9 1894/4885MAPK10 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.